Natalizumab induction and maintenance therapy for Crohn's disease

New England Journal of Medicine

Volumn 353, Issue 18, 2005, Pages 1912-1925

  Sandborn, William J ^a   Colombel, Jean Frédéric ^b   Enns, Roberts ^c   Feagan, Brian G ^d   Hanauer, Stephen B ^e   Lawrance, Ian C ^f   Panaccione, Remo ^g   Sanders, Martin ^h   Schreiber, Stefan ⁱ   Targan, Stephan ^j   Van Deventer, Sander ^k   Goldblum, Ronald ^l   Despain, Darrin ^l   Hogge, Gary S ^l   Rutgeerts, Paul ^m  

^a MAYO CLINIC   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g UNIVERSITY OF CALGARY   (Canada)

^h ProPharma International Ventures   (United States)

ⁱ UNIVERSITY OF KIEL   (Germany)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l ELAN PHARMACEUTICALS   (United States)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; PLACEBO;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; HEADACHE; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PERIANAL ABSCESS; PHARYNGITIS; PRIORITY JOURNAL; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SEPSIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINITIS; VIRUS MENINGITIS; VIRUS PNEUMONIA; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; CELL ADHESION MOLECULES; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTEGRIN ALPHA CHAINS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 27644441529     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa043335     Document Type: Article

References (14)

1. Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol 2003;98:2372-82.
2. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74.
3. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
4. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 1999;53:466-72.
5. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
6. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-44.
7. Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double-blind, placebo-controlled trial. Gut 2004;53:1485-93.
8. Schreiber S, Rutgeerts P, Fedorak R, et al. A randomized, placebo-controlled trial of sertolizumab pegol (CDP870) for the treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
9. Hommes D, Mikhajlova T, Stoinov S, et al. Fontolizumab (HuZAF™), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease (CD). Gastroenterology 2004;127:332. abstract.
10. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257-69.
11. Tysabri (natalizumab). San Diego, Calif.: Elan, November 2004 (package insert).
12. Kleinschmidt BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74.
13. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
14. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.